# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k062737   
B. Purpose for Submission: Notification of intent to manufacture and their associated controls and calibrators PENTRA CK NAC CP, ABX PENTRA ABX PENTRA Immuno II Control L/H, PENTRA N Control, ABX PENTRA P   
C. Measurand: Total creatine kinase and myoglobin   
D. Type of Test: Quantitative   
E. Applicant: Horiba ABX   
F. Proprietary and Established Names: ABX PENTRA CK NAC CP ABX PENTRA Myoglobin CP ABX PENTRA CK Control ABX PENTRA Immuno II Control L/H ABX PENTRA Myoglobin Cal ABX PENTRA N Control ABX PENTRA P Control ABX PENTRA Multical

# G. Regulatory Information:

1. Regulation section: 21 CFR 862.1215 : Creatine phosphokinase/creatine kinase or isoenzymes test system 21 CFR 866.5680 : Myoglobin immunological test system 21 CFR 862.1150 : Calibrator 21 CFR 862.1660 : Quality control materials (assayed)

2. Classification:

Class II (Assays)   
Class II (Calibrator)   
Class I (Control materials), reserved

3. Product code: CGS, NAD reduction/NADH oxidation, Cpk or isoenzymes DDR, Myoglobin, antigen, antiserum, control JJY, Quality control material (assayed and unassayed) JIX, Calibrator, multi-analyte mixture JIT, Secondary calibrator

4. Panel: Clinical Chemistry (75) Immunology (82)

# H. Intended Use:

1. Intended use(s):

Cardiac Markers reagents, with associated calibrators and controls, are intended for use on ABX PENTRA 400 Clinical Chemistry Analyzer to measure cardiac marker analytes.

ABX PENTRA CK-NAC CP reagent with associated calibrators and controls are for quantitative in vitro diagnostic determination of the total creatine kinase in human serum and plasma based on an optimized UV test. Measurements of creatine phosphokinase and its isoenzymes are used in the diagnosis and treatment of myocardial infarction and muscle diseases such as progressive, Duchenne-type muscular dystrophy.

The ABX PENTRA CK Control is for use in quality control by monitoring accuracy and precision for the quantitative ABX PENTRA CK-NAC method.

ABX PENTRA Myoglobin CP reagent with associated calibrators and controls are for quantitative in vitro diagnostic determination of myoglobin (an oxygen storage protein found in muscle) in human serum and plasma based on a latexenhanced immunoturbidimetric assay. Measurements of myoglobin aids in the rapid diagnosis of heart or renal disease.

The ABX PENTRA Myoglobin Cal is a calibrator for use in the calibration of quantitative Horiba ABX PENTRA Myoglobin CP method on Horiba ABX clinical chemistry analyzers.

The ABX PENTRA Immuno II Control L/H is for use in quality control by monitoring accuracy and precision.

The ABX PENTRA Multical is a calibrator for use in the calibration of quantitative Horiba ABX methods on Horiba ABX clinical chemistry analyzers.

The ABX PENTRA N Control is for use in quality control by monitoring accuracy and precision.

The ABX PENTRA P Control is for use in quality control by monitoring accuracy and precision.

2. Indication(s) for use: See Intended Use above.

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: ABX PENTRA 400

# I. Device Description:

All the reagents, controls and calibrators included in this submission are for use on the ABX PENTRA 400 (k052007), which is a discrete photometric benchtop clinical chemistry analyzer.

The ABX PENTRA CK NAC CP is an in vitro diagnostic assay for the quantitative determination of total creatine kinase in human serum and plasma based on an optimized UV test. The assay is composed of a bi-reagent cassette, with $2 6 ~ \mathrm { m l }$ and 6.5 ml compartments. Reagents are chemical solutions with additives.

The ABX PENTRA Myoglobin CP is an in vitro diagnostic assay for the quantitative determination of myoglobin in human serum and plasma based on a latex-enhanced immunoturbidimetric test. The assay is composed of a bi-reagent cassette, with $1 5 ~ \mathrm { m l }$ and $9 . 5 ~ \mathrm { m l }$ compartments. Reagents are chemical solutions with chemical additives and substances of animal origin.

The ABX PENTRA Myoglobin Cal is a liquid calibrator prepared from a dilution of purified myoglobin positive human sera. It is used for the calibration of the myoglobin assay. The assigned values are given on the vials. This calibrator is provided in five vials of $1 ~ \mathrm { m L }$ .

The ABX PENTRA CK Control is a lyophilized assayed control prepared from a bovine serum albumin with chemical additives and material of biological origin. It has to be used for the quality control of the creatine kinase assay. The assigned values are given in the enclosed annex. This calibrator is provided in 4 vials of $3 ~ \mathrm { m L }$ .

The ABX PENTRA Immuno II Control L/H is a lyophilized assayed control prepared from a stabilized pool of human sera. It has 2 levels (Low and High) to be used for the quality control of the myoglobin assay. The assigned values are given in the enclosed annex. Each level of this control is provided in one vial of $3 ~ \mathrm { m L }$ .

The ABX PENTRA Multical is a lyophilized human serum calibrator with chemical additives and materials of biological origin. The assigned values of the calibrator components are given in the enclosed annex, ensuring optimal calibration of the appropriate HORIBA ABX methods on the ABX PENTRA 400 analyzer. This calibrator is provided in ten vials of $3 ~ \mathrm { m l }$ . All products derived from blood are prepared exclusively from the blood of donors tested individually and shown by FDA-approved methods to be free from HBsAg and antibodies to HCV and HIV.

The ABX PENTRA N Control and ABX PENTRA P Control are quality control products consisting of lyophilized human serum with chemical additives and materials of biological origin added as required to obtain given component levels. The assigned values of the control components are given in the enclosed annexes, ensuring control of the appropriate HORIBA ABX methods on the ABX PENTRA 400 analyzer. Each control is provided in ten vials of $5 \mathrm { m l }$ . All products derived from blood are prepared exclusively from the blood of donors tested individually and shown by FDA-approved methods to be free from HBsAg and antibodies to HCV and HIV.

# J. Substantial Equivalence Information:

1. Predicate device name(s):

Roche CK NAC Reagent Set, Beckman Coulter ACCESS Myoglobin Reagent, Pointe Scientific CK-MB Control Set Level I/Level II, Bio-Rad Liquicheck Cardiac Markers Control Level 2, Beckman Coulter ACCESS Myoglobin Calibrators, ABX Pentra Multical and ABX Pentra N Control.

2. Predicate 510(k) number(s): k834502, k021229, k954074, k961828, k021229, k060854

3. Comparison with predicate:

<table><tr><td colspan="1" rowspan="1">cYanmaGellowb</td><td colspan="1" rowspan="1">Predicate device (k834502):</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">CK NAC</td><td colspan="1" rowspan="1">ABX Pentra CK NAC CP</td></tr><tr><td colspan="1" rowspan="1">Manufactured by</td><td colspan="1" rowspan="1">Roche, USA</td><td colspan="1" rowspan="1">HORIBA ABX, France</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">COBAS MIRA</td><td colspan="1" rowspan="1">ABX PENTRA 400</td></tr><tr><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">Creatine Kinase</td><td colspan="1" rowspan="1">Total Creatine Kinase</td></tr><tr><td colspan="1" rowspan="1">Method :</td><td colspan="1" rowspan="1">Optimized UV test</td><td colspan="1" rowspan="1">Optimized UV test</td></tr><tr><td colspan="1" rowspan="1">Specimen :</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Serum and plasma</td></tr><tr><td colspan="1" rowspan="1">Number of testsSample volumeDetection limitPrecisionMeasuring rangeUpper linearitylimitCalibrationstabilityClosed reagentstability</td><td colspan="1" rowspan="1">-4.4 μL/test-CV Total &lt; 1.6%2000 U/LUntil the expiration date whenstored at 2-8°Cafter reconstitution:</td><td colspan="1" rowspan="1">125 tests8 μL/test8 U/LCV Total &lt; 4.65%8 U/L - 1500 U/L1500 U/L, and with automatic post-dilution: 4500 U/L8 days18 months at 2-8°C</td></tr><tr><td colspan="1" rowspan="1">cYanmaGYellowb</td><td colspan="1" rowspan="1">Predicate device (k834502):</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">CK NAC</td><td colspan="1" rowspan="1">ABX Pentra CK NAC CP</td></tr><tr><td colspan="1" rowspan="1">Open reagentstability</td><td colspan="1" rowspan="1">6 days at 2-8C24 hours at 15-25°C</td><td colspan="1" rowspan="1">on-board stability (refrigeratedarea): 64 days</td></tr></table>

<table><tr><td></td><td>Predicate device (k021229):</td><td>Device :</td></tr><tr><td>Device Name</td><td>ACCESS Myoglobin Reagent</td><td>ABX Pentra Myoglobin CP</td></tr><tr><td>Manufactured by</td><td>BECKMAN COULTER Inc.</td><td>HORIBA ABX, France</td></tr><tr><td>Instrument</td><td>ACCESS Immunoassay systems (Access II analyzer)</td><td>ABX PENTRA 400</td></tr><tr><td>Analytes</td><td>Myoglobin</td><td>Myoglobin</td></tr><tr><td>Method :</td><td>Paramagnetic particle and chemiluminescent immunoassay.</td><td>Latex-enhanced</td></tr><tr><td>Specimen :</td><td>Serum and plasma</td><td>immunoturbidimetric assay. Serum and plasma</td></tr><tr><td>Number of tests</td><td>100 tests</td><td>100 tests</td></tr><tr><td>Sample volume</td><td>20 μL/test</td><td>14 μL/test</td></tr><tr><td>Detection limit</td><td>&lt; 1 μg/L (ng/mL)</td><td>6.7 μg/L (ng/mL)</td></tr><tr><td>Precision</td><td>CV Total &lt; 4.54%</td><td>CV Total &lt; 5.24%</td></tr><tr><td>Measuring range</td><td>13.8 µg/L − 3650.9 µg/L</td><td>20.4 µg/1 − 500 µg/L</td></tr><tr><td>Upper linearity limit</td><td>4000 μg/L</td><td>500 µg/1, and with automatic post- dilution: 2500 μg/L</td></tr><tr><td>Calibration stability</td><td>56 days</td><td>21 days</td></tr><tr><td>Closed reagent stability</td><td>Until the expiration date when stored at 2-10°C</td><td>12 months at 2-8°C</td></tr><tr><td>Open reagent stability</td><td>Open pack: 56 days at 2-10°C</td><td>On-board stability (refrigerated): 35 days</td></tr></table>

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Predicate device (k954074):</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">CK-MB Control Set Level I ,Level II</td><td colspan="1" rowspan="1">ABX Pentra CK Control</td></tr><tr><td colspan="1" rowspan="1">Manufactured by</td><td colspan="1" rowspan="1">POINTE SCIENTIFIC, INC.AALTO SCIENTIFIC, INC,</td><td colspan="1" rowspan="1">HORIBA ABX, France</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">COBAS MIRA Plus</td><td colspan="1" rowspan="1">ABX PENTRA 400</td></tr><tr><td colspan="1" rowspan="1">Method :</td><td colspan="1" rowspan="1">Single parameter control bymonitoring the performances ofCK-MB determination withCreatine Kinase-MB ReagentSet</td><td colspan="1" rowspan="1">Bi-parameter control bymonitoring accuracy andprecision for the quantitativeMethods as specified in theenclosed value sheet.Concentrations and activities aremostly in the normal or at thenormal/pathological threshold.</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">EY</td><td colspan="1" rowspan="1"></td></tr><tr><td>Device Name</td><td>CK-MB Control Set Level I , Level II</td><td>ABX Pentra CK Control</td></tr><tr><td>Biological additives</td><td>Human derived isoenzymes</td><td>CK-MM (Human origin) CK-MB (porcine brain origin)</td></tr><tr><td>Controlled molecules Theoretical values and confidence intervals</td><td>CK-MB: the exact control values are given on the vial label. - The assay value and range are established using the manufacturer's CK-MB reagent. - The assigned values and</td><td>Total Creatine Kinase (CK- NAC): the exact control values are given in the enclosed annex. - The assigned values are determined by calibration with a reference material in accordance with established protocols. - The assigned values and precise</td></tr><tr><td rowspan="2">Closed stability</td><td>range are indicated on the vial label.</td><td>confidence interval are indicated in the annex enclosed in the kit. - The assigned values are lot-</td></tr><tr><td>- The values are lot-specific.</td><td>specific.</td></tr><tr><td>Components</td><td>Until the expiration date when stored at 2-8°C At 2 - 8°C : 7 days</td><td>18 months at 2-8°C</td></tr><tr><td>stability after reconstitution of the calibrator</td><td></td><td>At 15 - 25°C : 24 hours At 2 - 8°C : 3 days</td></tr></table>

<table><tr><td colspan="1" rowspan="1">cYanmaGellowb</td><td colspan="1" rowspan="1">Predicate device (k961828):</td><td colspan="1" rowspan="1">Device :</td></tr><tr><td colspan="1" rowspan="1">Device Name</td><td colspan="1" rowspan="1">Liquicheck Cardiac MarkersControl, level 2</td><td colspan="1" rowspan="1">ABX Pentra Immuno II ControlL/H</td></tr><tr><td colspan="1" rowspan="1">Manufactured by</td><td colspan="1" rowspan="1">Bio-Rad</td><td colspan="1" rowspan="1">HORIBA ABX, France</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">ACCESS Immunoassay systems(Access II analyzer)</td><td colspan="1" rowspan="1">ABX PENTRA 400</td></tr><tr><td colspan="1" rowspan="1">Method :</td><td colspan="1" rowspan="1">Quality control by monitoringthe precision of laboratorytesting procedures listing in thepackage insert</td><td colspan="1" rowspan="1">Quality control by monitoringaccuracy and precision for thequantitative methods as specifiedin the enclosed value sheet.</td></tr><tr><td colspan="1" rowspan="1">Controlled molecules</td><td colspan="1" rowspan="1">Myoglobin, Troponin I,Troponin T, CK Total, LD-1isoenzyme, CK-MB isoenzyme.The exact control values aregiven in the notice.</td><td colspan="1" rowspan="1">Myoglobin, Ferritin.The exact control values aregiven in the enclosed annex.</td></tr><tr><td colspan="1" rowspan="1">Assigned values</td><td colspan="1" rowspan="1">- The assigned values aredetermined by calculating themean value obtained fromreplicate analyses.- The assay values are listed inthe notice enclosed in the kit.</td><td colspan="1" rowspan="1">- The assigned values specifiedare determined by calculatingthe mean value obtained frommultiple determinations.- The assigned values areindicated in the notice enclosedin the kit.</td></tr><tr><td colspan="1" rowspan="1">Closed stabilityOpen stability</td><td colspan="1" rowspan="1">- The values are lot specific2 years at -20°C to -10°CStability of Myoglobin,Troponin I, Troponin T:At 2 to 8°C :     10 daysStability of Total CK, CK-MB,LD-1:At 2 to 8°C :     20 days</td><td colspan="1" rowspan="1">- The assigned values for bothLow and High controls are lot-specific24 months at 2-10°C2 weeks at 2-10°C3 months at −20°C</td></tr></table>

<table><tr><td rowspan=1 colspan=1>canmaGellowb</td><td rowspan=1 colspan=1>Predicate device (k021229):</td><td rowspan=1 colspan=1>Device :</td></tr><tr><td rowspan=1 colspan=1>Device Name</td><td rowspan=1 colspan=1>ACCESS Myoglobin Calibrators</td><td rowspan=1 colspan=1>ABX Pentra Myoglobin Cal</td></tr><tr><td rowspan=1 colspan=1>Manufactured by</td><td rowspan=1 colspan=1>BECKMAN COULTER Inc.</td><td rowspan=1 colspan=1>HORIBA ABX, France</td></tr><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>ACCESS Immunoassay systems(Access II analyzer)</td><td rowspan=1 colspan=1>ABX PENTRA 400</td></tr><tr><td rowspan=1 colspan=1>Method :</td><td rowspan=1 colspan=1>Calibration of ACCESSMyoglobin assay</td><td rowspan=1 colspan=1>Calibration of HORIBA ABXMyoglobin methods</td></tr><tr><td rowspan=1 colspan=1>Calibrated molecules</td><td rowspan=1 colspan=1>Myoglobin</td><td rowspan=1 colspan=1>Myoglobin</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Liquid</td><td rowspan=1 colspan=1>Liquid</td></tr><tr><td rowspan=1 colspan=1>Calibration valueClosed stabilityOpen stability</td><td rowspan=1 colspan=1>- Assigned by proceduretraceable to the manufacturer&#x27;sworking calibrators and based onprEN ISO 17511.- The exact assigned values areindicated on each vial or oncalibration card(5 levels: approximately 50, 200,800, 2000 and 4000 ng/mL)Up to the expiration date at-20°C60 days at 2-10°C</td><td rowspan=1 colspan=1>- Determined using primarycalibration with in-housecalibrator adjusted tonephelometric method.- The assigned values areindicated on each vial ( 5 levels:0, 62.5, 125, 250 and 500ng/mL)12 months at 2-10°C7 weeks at 2-10°</td></tr></table>

ABX Pentra Multical and ABX Pentra N Control: Addition of creatine kinase.

# K. Standard/Guidance Document Referenced (if applicable):

1) Valtec protocol for evaluation of device performance: Vassault et al., Ann. Biol. Clin., 1986, (44), 686-745).

2) CLSI EP5-A2, Evaluation of Precision Performance of Quantitative Measurement Methods.   
3) CLSI EP6-A, Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach.   
4) CLSI EP9-A2, Method Comparison and Bias Estimation Using Patient Samples.   
5) CLSI EP17-A, Protocols for Determination of Limits of Detection and Limits of Quantitation.

# L. Test Principle:

For total creatine kinase, the reagents supplied cause a chemical reaction which produces an amount of gluconate-6-phosphate+NADPH $\mathrm { + H ^ { + } }$ which is proportional to the amount of creatine kinase in the sample.

![](images/035a97e318b17e82fee9303396f5b12e457c1b339b0f0667787c673f0cda7c64.jpg)

For myoglobin, the method used in this assay is a turbidimetric immunoassay. When an antigen-antibody reaction occurs between Mb in a sample and anti-Mb antibody which has been sensitized to latex particles, agglutination results. This agglutination is detected as an absorbance change, with the magnitude of the change being proportional to the quantity of Mb in the sample. The actual concentration is then determined by interpolation from a calibration curve prepared from calibrators of known concentration.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Within Run: For the CK NAC (total CK) reagent, within-run precision was determined using 2 controls (ABX PENTRA N and P Controls) and 3 serum specimens of low, medium and high concentrations were tested 20 times in a single run for each sample (in accordance with the Valtec guideline (Vassault et al., Ann. Biol. Clin., 1986, (44), 686-745). Results are described below.

<table><tr><td rowspan=1 colspan=1>In U/L</td><td rowspan=1 colspan=1>N Control</td><td rowspan=1 colspan=1>P Control</td><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>166</td><td rowspan=1 colspan=1>474</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>347</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>2.54</td><td rowspan=1 colspan=1>1.14</td><td rowspan=1 colspan=1>0.79</td></tr></table>

For the Myoglobin reagent, within-run precision was determined using 2 controls (Immuno II Control L/H) and 3 serum specimens of low, medium and high concentrations tested 20 times in a single run for each sample (in accordance with the Valtec guideline (Vassault et al., Ann. Biol. Clin., 1986, (44), 686-745). Results are described below.

<table><tr><td rowspan=1 colspan=1>In ng/mL</td><td rowspan=1 colspan=1>L Control</td><td rowspan=1 colspan=1>H Control</td><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>Sample 3</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>66.9</td><td rowspan=1 colspan=1>207.4</td><td rowspan=1 colspan=1>27.9</td><td rowspan=1 colspan=1>46.7</td><td rowspan=1 colspan=1>330.3</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>1.53</td><td rowspan=1 colspan=1>1.18</td><td rowspan=1 colspan=1>4.26</td><td rowspan=1 colspan=1>3.56</td><td rowspan=1 colspan=1>0.54</td></tr></table>

# Between Run:

For the CK NAC reagent, between-run precision NCCLS (CLSI) EP-5A was followed using two serum specimens of low & high levels and 2 controls tested in duplicate for 20 days, two series per day (for a total of 80). Results are described below.

<table><tr><td rowspan=2 colspan=1>In U/L</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N Control</td><td rowspan=1 colspan=1>P Control</td><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>162</td><td rowspan=1 colspan=1>489</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>311</td></tr><tr><td rowspan=2 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>8.34</td><td rowspan=1 colspan=1>2.26</td><td rowspan=1 colspan=1>3.62</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>2.28</td><td rowspan=1 colspan=1>1.78</td><td rowspan=1 colspan=1>2.76</td><td rowspan=1 colspan=1>1.13</td></tr><tr><td rowspan=2 colspan=1>Total</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>4.14</td><td rowspan=1 colspan=1>11.71</td><td rowspan=1 colspan=1>3.78</td><td rowspan=1 colspan=1>8.12</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>2.56</td><td rowspan=1 colspan=1>2.50</td><td rowspan=1 colspan=1>4.65</td><td rowspan=1 colspan=1>2.61</td></tr></table>

For the Myoglobin reagent, between-run precision NCCLS (CLSI) EP-5A was followed using two serum specimens of low & high levels and 2 controls tested in duplicate for 20 days, two series per day (for a total of 80). Results are described below.

<table><tr><td rowspan=2 colspan=1>In ng/mL</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>L Control</td><td rowspan=1 colspan=1>H Control</td><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>Sample 2</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>67.5</td><td rowspan=1 colspan=1>201.2</td><td rowspan=1 colspan=1>58.8</td><td rowspan=1 colspan=1>389.3</td></tr><tr><td rowspan=2 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.66</td><td rowspan=1 colspan=1>5.02</td><td rowspan=1 colspan=1>1.65</td><td rowspan=1 colspan=1>10.00</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>2.47</td><td rowspan=1 colspan=1>2.49</td><td rowspan=1 colspan=1>2.81</td><td rowspan=1 colspan=1>2.57</td></tr><tr><td rowspan=2 colspan=1>Total</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>2.99</td><td rowspan=1 colspan=1>10.55</td><td rowspan=1 colspan=1>2.46</td><td rowspan=1 colspan=1>17.08</td></tr><tr><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>4.43</td><td rowspan=1 colspan=1>5.24</td><td rowspan=1 colspan=1>4.18</td><td rowspan=1 colspan=1>4.39</td></tr></table>

# $b$ . Linearity/assay reportable range:

Linearity for CK NAC was assessed for non-post dilution samples in accordance with CLSI EP6-A. Samples used for this study were in house preparations of CK aqueous solution. Two different studies with ten different levels of total CK (each tested 4 times except for lowest dilution of the low level study which was sampled twice) were prepared based on the dilution of the highest concentration solution level with a solution near the low limit of detection resulting in a range of samples from 8.48 to $1 4 7 \mathrm { U } / \mathrm { L }$ and 81.38 to $1 5 1 0 \mathrm { U / L }$ . The linearity of the CK NAC assay was evaluated by comparing observed versus expected values across the expected range. A linear regression analysis was performed on the data and plotted. The sponsor’s acceptable bias for recovery of the samples is $\pm 8 \%$ . The observed linearity across the 8.48 to $1 4 7 \mathrm { U } / \mathrm { L }$ range has a slope of 0.993, and an intercept of 0.5558. The observed linearity across the 81.38 to $1 5 1 0 \mathrm { U / L }$ range has a slope of 0.9995, and an intercept of 0.3936. The assay range was demonstrated to be linear from 8.48 to $1 5 1 0 \mathrm { U / L }$ . The sponsor will claim a range of 8 (the detection limit) to $1 5 0 0 \mathrm { U / L }$ . Recovery of post dilution serum samples was also assessed comparing manual versus automatic dilution by the PENTRA 400. Five serum samples were each tested 4 times and ranged from 1610 to $4 2 6 3 \mathrm { U } / \mathrm { L }$ . The sponsor’s acceptable bias for recovery of the samples is $\pm 1 0 \%$ . The data supports the sponsor’s claim of a post dilution limit of 4500 U/L.

Linearity for Myoglobin was assessed for non-post dilution samples in accordance with CLSI EP6-A. Samples used for this study were human serum. Eleven different levels of myoglobin (each tested 4 times) were prepared based on the dilution of the highest concentration solution level with a solution near the low limit of detection resulting in a range of samples from 48 to $4 8 2 . 6 \mathrm { n g / m L }$ . The linearity of the assay was evaluated by comparing observed versus expected values across the expected range. A linear regression analysis was performed on the data and plotted. The sponsor’s acceptable bias for recovery of the samples is $\pm 1 0 \%$ . The observed linearity across the reportable range has a slope of 0.9998, and an intercept of 0.0667. The assay range was demonstrated to be linear from 48 to $4 8 2 . 6 \mathrm { n g / m L }$ . The sponsor will claim a range of 20.4 (the lowest value of the comparison study) to $5 0 0 ~ \mathrm { { n g / m L } }$ (the value of the highest calibrator). The lower values of 20.4 to 48 where found to be acceptable for the claimed range as the predicate device included this range in its claim and the sponsor showed equivalence at these levels. Recovery of post dilution serum samples was also assessed comparing manual versus automatic dilution by the PENTRA 400. Seven samples were each tested 4 times and ranged from 513.9 to $2 3 0 1 . 1 \ \mathrm { n g / m L }$ . The sponsor’s acceptable bias for recovery of the samples is $\pm 1 0 \%$ . The data supports the sponsor’s claim of a post dilution limit of $2 5 0 0 ~ \mathrm { n g / m L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods): Real time stability at $8 ^ { \circ } \mathrm { C }$ was investigated for Myoglobin calibrator. Recovery of the values for the calibration points in Myoglobin was assayed for 3 lots periodically over a period of 18 months. The closed stability study was performed over a period providing data to support the sponsor’s claim of closed stability between $2 \textrm { - } 1 0 ^ { \circ } \mathrm { C }$ for 12 months. Real time stability studies after opening were performed. Recovery of the values for the calibration points in Myoglobin was assayed for 1 lot periodically over a period of 7 weeks, providing data supporting a stability period of 7 weeks at $8 ^ { \circ } \mathrm { C }$ .

Real time stability at $8 ^ { \circ } \mathrm { C }$ was investigated for Immuno II Control L/H. Recovery of the values in Myoglobin and Ferritin for the Low and High controls was assayed for 3 lots during 27 to 29 months. The closed stability study was performed over a period providing data to support the sponsor’s claim of closed stability of 27 months at $8 ^ { \circ } \mathrm { C }$ . Stability after reconstitution and storage frozen at ${ } _ { - 2 0 } \mathrm { { } ^ { \circ } C }$ was investigated for Immuno II Control L/H.

Stability studies after reconstitution were performed providing data supporting a stability of 3 months at $- 2 0 ^ { \circ } \mathrm { C }$ for ABX Pentra Immuno II Control L/H after reconstitution and a closed stability of 24 months between $2 \textrm { - } 1 0 ^ { \circ } \mathrm { C }$ .

For ABX PENTRA N Control & ABX PENTRA P Control traceability, the values of the ABX PENTRA Controls are assigned from the ABX PENTRA calibrator, reagents and analyzers. The target value is determined by the median of results from 150 measurements/parameters. Confidence range is determined as the calculated range in percent which is based on the experimental results from the previous target value trials. The range declared in the target value sheet is equal to the assigned value $+ / - 3$ standard deviations (3 SD).

For ABX Pentra Multical traceability, the ABX Pentra Multical is prepared from reference materials. Commercial calibrators are standardized by means of a master lot which is stored at $- 8 0 ^ { \circ } \mathrm { C }$ . Two controls are used to ensure that the calibration values of the master lot, as well as the entire measurement system (calibrator, reagent, and analyzer), remain stable during the storage period. The target value is determined by the median of results from 150 measurements/parameters.

For the ABX PENTRA N Control, ABX PENTRA P Control, and ABX PENTRA Multical, protocols and acceptance criteria for open and closed stability of the controls and calibrators were described and found to be acceptable.

# d. Detection limit:

The detection limit for the CK NAC was determined by measuring 30 measurements of saline water $( \mathrm { N a C l } 0 . 9 \mathrm { g / L } ) + 4 . 6 5$ SD. The limit of detection for the CK NAC assay was determined to be $8 \ : \mathrm { U / L }$ .

Because the measurement of saline water is not possible with the normal application of the Myoglobin assay (no results available when sample concentration is lower than the calibration curve), usual measurement of MDL (30 measurements of saline water) is not possible. For the specific proteins the Minimum Interpretation Limit (MIL) is used. Like MDL, MIL is the lower concentration that could be distinguished from 0, concentration calculated using the rate absorbency measurement of known concentration’s samples and saline water. The limit of detection for the Myoglobin assay was determined to be $6 . 7 \mathrm { n g / m L }$ .

# e. Analytical specificity:

For CK NAC: In accordance with the Valtec guideline, the tested interferants were added to base serum at two different CK concentrations (normal and high). The base serum with each substance was then serially diluted with the same base serum and saline to adjust CK concentration. Hemoglobin up to 55 $\mathrm { \mu \ m o l / l \left( 9 7 \ m g / d L \right) }$ , total bilirubin up to $1 2 5 \mu \mathrm { m o l / L }$ $7 . 3 \mathrm { m g / d L } )$ , direct bilirubin up to $1 0 0 \ : \mu \mathrm { m o l } / 1$ $( 5 . 9 \mathrm { m g / d L } )$ and triglycerides (as Intralipid $\textsuperscript { \textregistered }$ , representative of lipemia) up to $7 \mathrm { m m o l } / \mathrm { L }$ ( $6 1 2 . 5 \mathrm { m g / d L } )$ ) do not interfere with CK determination by this test.

For Myoglobin: Substances were added to the base serum at two different myoglobin concentrations (normal and high). The base serum with each substance was then serially diluted with the same base urine serum and saline to adjust myoglobin concentration. Hemoglobin up to $1 9 5 \mathrm { \ : \mu m o l / l }$ (336 $\mathrm { m g / d L ) }$ , total bilirubin up to $5 0 0 \mu \mathrm { m o l / L }$ $( 2 9 . 3 ~ \mathrm { m g / d L } )$ , direct bilirubin up to $5 0 0 \ \mathrm { \mu m o l }$ ( $2 9 . 3 \mathrm { m g / d L } )$ and triglycerides (as Intralipid $\textsuperscript { \textregistered }$ , representative of lipemia) up to $7 \mathrm { m m o l } / \mathrm { L }$ ( $6 1 2 . 5 \mathrm { m g / d L } )$ do not interfere with myoglobin determination by this test. The sponsor also determined a prozone effect for the Myoglobin assay to occur at $1 3 7 4 ~ \mathrm { { n g / m L } }$ with dilution being effective in overcoming the effect.

f. Assay cut-off: Not applicable.

2. Comparison studies:

a. Method comparison with predicate device:

A total of 175 serum and plasma samples were run using the CK NAC reagents on the PENTRA 400 and a reference method. Samples ranged from 8.0 to $1 4 0 8 \mathrm { U / L }$ . Diluted or spiked samples (59) were used to cover the range of the assay. Linear regression analysis gave the following relationship: Device $= 1 . 0 5 6$ (Predicate) – 2.253; $\mathbf { r } = 0 . 9 9 6 7$ .

A total of 90 serum and plasma samples were run using the Myoglobin reagents on the PENTRA 400 and a reference method. Clinical non-spiked samples ranged from 20.4 to $4 8 4 ~ \mathrm { { n g / m L } }$ . Linear regression analysis gave the following relationship: Device $= 0 . 9 2 0$ (Predicate) $+ 2 2 . 2 5 1$ ; $\mathbf { r } = 0 . 9 8 7 6$ .

b. Matrix comparison:

The sponsor demonstrated equivalence of CK NAC results in serum and Lithium Heparin plasma samples by using 42 clinical samples spanning a range of 29 to $1 1 9 7 \mathrm { U / L }$ . Linear regression showed a slope of 0.96 and an intercept of 1.04, and a correlation coefficient of 0.999.

The sponsor demonstrated equivalence of Myoglobin results in serum and Lithium Heparin plasma samples by using 69 clinical samples spanning a range of 19 to $2 3 6 ~ \mathrm { { n g / m L } }$ . Linear regression showed a slope of 1.01 and an intercept of 2.12, and a correlation coefficient of 0.9959.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.

b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: The reference range for CK NAC is indicated to be:

Adults: Women $< 1 4 5 \mathrm { U / L }$ Men $< 1 7 1 \ \mathrm { U / L }$

Reference:   
IFCC Primary Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at $3 7 ^ { \circ } \mathrm { C }$ ; Part 2 ; Clin Chem Lab Med 2002; 40(6) : 635-642.

The reference range for Myoglobin is indicated to be: $7 0 - 1 1 0 \mathrm { n g / m L }$ $( \mu \mathrm { g } / \mathrm { L } )$

Reference :   
Thomas L. Clinical Laboratory Diagnostics. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft; 1998. p. 106.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.